Data sourced from Dakota Private Markets, the private fund performance platform powered by Dakota. Learn More | Request Access
For deal sourcers, staying current on private company activity is critical to spotting active buyers, tracking market trends, and uncovering emerging investment opportunities ahead of competitors.
In August alone, we added more than 2,000 new private company transactions, bringing the total to over 30,000+ searchable deals across sectors, industries, and transaction types in Dakota Private Markets
Inside Dakota Private Markets, you’ll find the transactions tab that provides structured, filterable data on deal types, values, and dates, while our editorial team curates daily updates through the Dakota transactions newsletter, helping you cut through the noise and focus on what matters most.
To ensure the most comprehensive coverage of private market activity, Dakota’s team monitors over 10,000 websites including company websites, newswires, and numerous third-party news providers to capture and verify transaction data as it happens.
Below are the top 10 health care transactions.
- Transaction Date: 8/3/2026
- Industry: Pharmaceuticals
- Type: Buyout / Private Equity
- Transaction Value: $8B
Curium, backed by CapVest, will merge with Lantheus for $102.50 per share in cash plus CVRs worth up to $12.00 per share tied to commercial milestones through 2030, for total consideration of up to $114.50 per share and a transaction value of up to $8.0 billion. The combination creates a radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries, uniting Lantheus' US commercial infrastructure (PYLARIFY, DEFINITY, Neuraceq) with Curium's global manufacturing and theranostics pipeline, with closing expected in H1 2027.
- Transaction Date: 8/4/2026
- Industry: Consumer Health & Wellness
- Type: Acquisition / Merger
- Transaction Value: $3.8B
Procter & Gamble will acquire Thorne, a science-backed supplement and personalized health brand, from L Catterton's Flagship Fund for $3.8 billion. The deal strengthens P&G's Personal Health Care business in premium wellness, with Thorne continuing to operate under CEO Colin Watts and closing expected later in 2026.
- Transaction Date: 8/31/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $2.86B
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone payments, gaining lead program MER511—a Phase 1 biologic designed to selectively degrade the autoantibodies causing Graves' disease and thyroid eye disease. The deal also adds Merida's earlier-stage pipeline targeting food allergy, asthma, and kidney diseases through the same precision antibody-degradation platform, with closing expected in Q4 2026.
- Transaction Date: 8/25/2026
- Industry: Life Sciences Tools & Services
- Type: Acquisition / Merger
- Transaction Value: $2.25B
McKesson will acquire Precision Medicine Group, a clinical research and biopharma commercialization services provider, for approximately $2.25 billion. Precision Medicine Group will operate within McKesson's Oncology & Multispecialty segment, adding biomarker intelligence, lab services, clinical trial capabilities, and market access consulting, subject to customary regulatory approvals.
- Transaction Date: 8/21/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $1.75B
Ipsen has completed its acquisition of Kartos Therapeutics for $450 million upfront plus up to $1.3 billion in regulatory and sales milestones, gaining navtemadlin—a Phase III MDM2 inhibitor being studied as an add-on to ruxolitinib in myelofibrosis patients with suboptimal responses to standard care. The deal expands Ipsen's late-stage hemato-oncology pipeline, with the drug targeting a potential launch as early as 2028 and expected to be accretive to Ipsen's core operating income from 2029.
Want to track health care deal activity like this as it happens? Explore the full transactions tab in Dakota Private Markets for real-time, filterable data on every deal in this sector.
- Transaction Date: 8/6/2026
- Industry: Health Care Providers & Services
- Type: Buyout / Private Equity
- Transaction Value: $1.39B
KKR will acquire Medicover Hospitals India, a 24-hospital, ~4,800-bed multi-specialty network across South and West India, from Medicover AB and minority partners, valuing the business at €1.2 billion enterprise value. Medicover will receive gross cash proceeds of €0.74 billion, freeing it to focus on accelerated growth in Poland, Germany, and Romania, with closing expected in Q4 2026 pending regulatory approvals.
- Transaction Date: 8/10/2026
- Industry: Health Care Equipment & Supplies
- Type: Acquisition / Merger
- Transaction Value: $1.1B
Teledyne Technologies will acquire Varex Imaging, an X-ray tube and digital detector maker, for $18.90 per share in cash, valuing the deal at approximately $1.1 billion. The acquisition adds Varex's high-radiation-environment detectors and photon counting technology to Teledyne's existing healthcare imaging portfolio, with minimal product overlap, and is expected to close in early 2027 pending regulatory and shareholder approvals.
- Transaction Date: 8/3/2026
- Industry: Pharmaceuticals
- Type: Buyout / Private Equity
- Transaction Value: $800M
BWX Technologies will sell its medical business, including BWXT Medical and Kinectrics' stable isotopes unit, to Nordic Capital in a deal valued at up to $800 million, while retaining a minority ownership stake. The move lets BWXT focus resources on its core nuclear national security and commercial nuclear power markets, with the medical business set to scale under Nordic Capital's radiopharmaceutical expertise, and closing expected by year-end 2026.
- Transaction Date: 8/25/2026
- Industry: Health Care Providers & Services
- Type: Acquisition / Merger
- Transaction Value: $715.85M
Radiology Partners will acquire Everlight Radiology from Livingbridge, combining Everlight's international network of over 800 radiologists across 40+ countries with RP's US-based vRad teleradiology platform to form a global teleradiology leader. Financial terms weren't disclosed, but the deal aims to address radiologist shortages worldwide by sharing AI tools and clinical standards, with Everlight continuing under its current management team pending regulatory approval.
- Transaction Date: 8/6/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $450M
Tarsus Pharmaceuticals will acquire Alkeus Pharmaceuticals for approximately $450 million upfront ($270 million cash, $180 million stock) plus up to $350 million in regulatory and sales milestones, gaining gildeuretinol—a Phase 3 oral therapy for Stargardt disease, an inherited retinal disorder with no FDA-approved treatments. The deal expands Tarsus' retina franchise alongside its existing IRX-101 program, with Phase 3 topline data expected in H2 2029 and closing anticipated in 2026.
At Dakota, we understand how important it is to stay current on deal activity as it happens. That’s why our editorial team continuously monitors the news for real-time updates on platform investments, add-ons, divestitures, and more to deliver daily highlights straight to your inbox through our transactions newsletter.
Inside Dakota Private Markets, the transactions tab provides structured, filterable data with deal dates, types, sectors, and financials, allowing you to build a customized feed that aligns with your focus areas.
Whether you're evaluating a new investment opportunity or tracking trends within a target sector, Dakota helps you cut through the noise and focus on what matters most.
For more information on these transactions and a deeper dive into their industries and sub-industries, request access to Dakota Private Markets.
